The evaluation of suppressive effects concerning tumor metastasisusing soluble VEGF-C receptor
Project/Area Number |
22501018
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Tumor biology
|
Research Institution | Kitasato University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KATAGIRI Masato 北里大学, 医療衛生学部, 教授 (50152674)
MAJIMA Masataka 北里大学, 医学部, 教授 (70181641)
MATSUMOTO Kazumasa 北里大学, 医学部, 講師 (70306603)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | リンパ管新生 / 細胞療法 / 癌転移 / リンバ管新生 |
Research Abstract |
The suppressive effects of lymphangiogenesis using mouse soluble vascular endothelial growth factor (VEGF)-C receptor (sVegfr-2) cDNA introduced mouse embryonic fibroblast cells (C57-sVegfr-2) and Lweis lung carcinoma cells (LLC-sVegfr-2) were evaluated. The production of svegfr-2 and strong binding effect with VEGF-C in the supernatant of C57-sVegfr-2 were verified in vitro by Western blotting and immune -precipitation, respectively. The lymphangiogenesis was significantly reduced in primary lesion, followed by inoculation of LLC-sVegfr-2 into C57 mice, in vivo
|
Report
(4 results)
Research Products
(20 results)
-
-
[Journal Article] Thromboxane A_2 receptor signaling facilitates tumor colonization through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells2012
Author(s)
Matsui Y, Amano H, Ito Y, Eshima K, Suzuki T, Ogawa F, Iyoda A, Satoh Y, Kato S, Nakamura M, Kitasato H, Narumiya S, Majima M
-
Journal Title
Cancer Sci
Volume: 103(4)
Issue: 4
Pages: 700-7
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-